Clinical Trials: Prevention and Screening
Prevention Trials
Therapeutic Area: Breast Cancer
Principal Investigator: Dr.
Carolyn Runowicz
Title: A
phase III randomized study of exemestane vs. placebo in
postmenopausal women at increased risk of developing breast
cancer
Description:
In this trial, a sample of women who are at high-risk for
breast cancer randomly will be placed into one of two
groups; the group that will receive exemestane or the group
that will receive the placebo (sugar pill). Women who
participate in this study will need to take one pill a day
for the next five years. Neither the participant nor the
doctor/staff will know to which group the individual has
been randomly placed. The investigators want to learn
if exemestane is effective in preventing breast cancer in
women that are at an increased risk of developing the
disease.
Length/Duration:
5 years
Compensation:
None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 06-163
Sponsor: National Cancer Institute
of Canada
Principal Investigator:
Dr. Carolyn Runowicz
Title:
Collection of Clinical Samples from Patients at High Risk
for Ovarian Cancer for Biomarker Studies
Description:
The purpose of this study to determine the clinical utility
of a panel of ovarian cancer markers to screen patients at
high-risk for the development of ovarian cancer. This study
will examine blood taken from patients with and without
ovarian cancer and analyzed for the presence or absence of
the identified markers.
Length/Duration:
1 hour
Compensation:
None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 06-160
Sponsor:
Tripath
Screening Trials
Therapeutic Area: Breast Cancer
Principal Investigator: Dr. Scott Kurtzman
Title: Serial Evaluation of Ductal Epithelium (SEDE) and Breast Health Outcomes in Women at High Risk for Breast Cancer
Description: In this trial, a sample of women who are at high-risk for breast cancer and who have no evidence of breast malignancy, will be followed over an approximate
five-year period. Subjects will undergo a ductal lavage procedure on a serial basis and overall breast health will be recorded based on physical exam and mammograms.
Length/Duration:
5 years
Compensation: Maximum of $100.00
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to
dnoel@uchc.edu
IRB #: 05-005
Sponsor: Cytyc Corporation |
Research
done today will be the standard treatments of tomorrow.